• 1
    ) Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P. and Massague, J. Cloning of p27/Kip1, a cyclin dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 5966 (1994).
  • 2
    ) Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M. and Kemp, C. J. The murine gene p27/Kip1 is haplo-insufficient for tumour suppression. Nature, 396, 177 (1998).
  • 3
    ) Fredersdorf, S., Burns, J., Milne, A. M., Packham, G., Fallis, L., Gillett, C. E., Royds, J. A., Peston, D., Hall, P. A., Hanby, A. M., Barnes, D. M., Shousha, S., O'Hare, M. J. and Lu, X. High level expression of p27/Kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27/Kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA, 94, 63806385 (1997).
  • 4
    ) Loda, M., Cukor, B. and Tam, S. W. Increased proteasome- dependent degradation of the cyclin dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nat. Med., 3, 231234 (1997).
  • 5
    ) Ciaparrone, M., Yamamoto, H., Yao, Y., Sgambato, A., Cattoretti, G., Tomita, N., Rotterdam, H. and Weinstein, I. B. Localization and expression of p27/Kip1 in multistage colorectal carcinogenesis. Cancer Res., 58, 114122 (1998).
  • 6
    ) Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R. and Roberts, J. M. Expression of cell-cycle regulators p27/Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3, 222225 (1997).
  • 7
    ) Catzavelos, C., Bhatacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Moravaprotzner, I., Kapusta, L., Franssen, E., Pritchard, K. I. and Slingerland, J. M. Decreased levels of the cell-cycle inhibitor p27/Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3, 227230 (1997).
  • 8
    ) Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Ueo, H., Sumimachi, K. and Akiyoshi, T. p27 expression and gastric carcinoma. Nat. Med., 3, 593 (1997).
  • 9
    ) Yatabe, Y., Masuda, A., Koshikawa, T., Nakamura, S., Kuroishi, T., Osada, H., Takahashi, T., Mitsudomi, T. and Takahashi, T. p27/Kip1 in human lung cancers: differential changes in small cell and non small cell carcinomas. Cancer Res., 58, 10421047 (1998).
  • 10
    ) Tsihlias, J., Kapusta, L. R., DeBuer, G., Morava-Protzner, I., Zbieranowski, I., Bhattacharya, N., Catzavelos, G. C., Klotz, L. H. and Slingerland, J. M. Loss of cyclin dependent kinase inhibitor p27/Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58, 542548 (1998).
  • 11
    ) Jordan, R. C. K., Bradley, G. and Slingerland, J. Reduced levels of the cell cycle inhibitor p27/Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am. J. Pathol., 152, 585590 (1998).
  • 12
    ) Masciullo, V., Sgambato, A., Pacilio, C., Pucci, B., Ferrandina, G., Palazzo, J., Carbone, A., Cittadini, A., Mancuso, S., Scambia, G. and Giordano, A. Frequent loss of expression of the cyclin dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res., 59, 37903794 (1999).
  • 13
    ) Erickson, L. A., Jin, L., Wollan, P. C., Thompson, G. B., Van Heerden, J. and Lloyd, R. V. Expression of p27/Kip1 and Ki-67 in benign and malignant thyroid tumours. Mod. Pathol., 11, 169174 (1998).
  • 14
    ) Erlanson, M., Portin, C., Linderholm, B., Lindh, J., Roos, G. and Landberg, G. Expression of cyclin E and the cyclin dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood, 92, 770777 (1998).
  • 15
    ) Kudoh, S., Kumaravel, T. S., Kumaravel, B., Eguchi, M., Asaoku, H., Dohy, H., Fujiwara, M., Sasaki, N., Tanaka, K. and Kamada, N. Protein expression of cell cycle regulator, p27Kip1, correlates with histopathological grade of non- Hodgkin's lymphoma. Jpn. J. Cancer Res., 90, 12621269 (1999).
  • 16
    ) Vrhovac, R., Delmer, A., Tang, R., Marie, J. P., Zittoun, R. and Ajchenbaum-Cymbalista, F. Prognostic significance of the cell cycle inhibitor p27/Kip1 in chronic B-cell lymphocytic leukemia. Blood, 91, 46944700 (1998).
  • 17
    ) Pagano, M., Tam, S. W., Theodoras, A. M., Romero-Beer, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F. and Rolfe, M. Role of the ubiquitin proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science, 269, 682685 (1995).
  • 18
    ) Tomoda, K., Kubota, Y. and Kato, J. Y. Degradation of the cyclin dependent kinase inhibitor p27/Kip1 is instigated by Jab1. Nature, 398, 160165 (1999).
  • 19
    ) Claret, F. X., Hibi, M., Dhut, S., Toda, T. and Karin, M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature, 383, 453457 (1996).
  • 20
    ) Halevy, O., Novitch, B. G., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D. and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science, 267, 10181021 (1995).
  • 21
    ) Zabludoff, S. D., Csete, M., Wagner, R., Yu, X. and Wold, B. J. p27/Kip1 is expressed transiently in developing myotomes and enhances myogenesis. Cell Growth Differ., 9, 11 (1998).
  • 22
    ) Durand, B., Gao, F. B. and Raff, M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J., 16, 306317 (1997).
  • 23
    ) Drissi, H., Hushka, D., Aslam, F., Nguyen, Q., Buffone, E., Koff, A., Wijnen, A. J. V., Lian, J. B., Stein, J. L. and Stein, G. S. The cell cycle regulator p27/Kip1 contributes to growth and differentiation of osteoblasts. Cancer Res., 59, 37053711 (1999).
  • 24
    ) World Health Organization. “Histological Typing of Soft Tissue Tumors, 2nd Ed.,” pp. 2930 (1994). WHO, Geneva .
  • 25
    ) Kindblom, J. M. M., Stenman, G. and Kindblom, L. G. Differential diagnosis of small round cell tumors. Semin. Diag. Pathol., 13, 213241 (1996).
  • 26
    ) Coffin, C. M., Dehner, L. P. and O'Shea, P. A. Pediatric Soft Tissue Tumors. A Clinical, Pathological, and Therapeutic Approach,” pp. 214253 (1997). Williams and Wilkins, Baltimore , MD .
  • 27
    ) Enzinger, F. M. and Weiss, S. W. Rhabdomyosarcoma, 4th Ed.,” pp. 785835 (2001). Mosby, St. Louis , MO .
  • 28
    ) Shen, L., Tsuchida, R., Miyauchi, J., Saeki, M., Honna, T., Tsunematsu, Y., Kayo, J. and Mizutani, S. Differentiationassociated expression and intracellular localization of cyclin-dependent kinase inhibitor p27Kip1 and c-Jun coactivator JAB1 in neuroblastoma. Int. J. Oncol., 17, 749754 (2000).
  • 29
    ) Carrano, A. C., Eytan, E., Hershko, A. and Pagano, M. SKP2 is required for ubiquitin mediated degradation of the CDK inhibitor p27. Nat. Cell Biol., 1, 193199 (1999).
  • 30
    ) Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J., Wilczynski, S., Lee, Y. Y., Bartram, C. R. and Koeffler, H. P. Molecular analysis of the cyclin dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res., 55, 22662269 (1995).
  • 31
    ) Sui, L., Dong, Y., Ohno, M., Watanabe, Y., Sugimoto, K., Tai, Y. and Tokuda, M. Jab1 expression is associated with inverse expression of p27/Kip1 and poor prognosis in epithelial ovarian tumors. Clin. Cancer Res., 7, 41304135 (2001).